A Multicenter Study to Obtain Data to Assist in Radiation Dosimetry Calculations From Subjects Enrolled in Human Studies Employing 18F-AV-1451

Avid Radiopharmaceuticals1 site in 1 country6 target enrollmentJanuary 2015

ConditionsAlzheimer's Disease

InterventionsFlortaucipir F18

DrugsFlortaucipir F18

Overview

Phase: Phase 1
Intervention: Flortaucipir F18
Conditions: Alzheimer's Disease
Sponsor: Avid Radiopharmaceuticals
Enrollment: 6
Locations: 1
Primary Endpoint: Urine Analysis - Total Integrated Radioactivity Excreted in Urine
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study will obtain data from urine in subjects administered flortaucipir in an Avid-sponsored study to augment the calculation of radiation dosimetry estimates.

Registry

clinicaltrials.gov

Start Date

January 2015

End Date

June 2015

Last Updated

5 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Avid Radiopharmaceuticals

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects who passed screening in an Avid-sponsored study in which flortaucipir will be administered

Exclusion Criteria

•Subjects who have withdrawn informed consent
•Investigator or sponsor believes it is in the best interest of the subject to be removed from the trials

Arms & Interventions

Urine Analysis

Urine will be collected from subjects administered flortaucipir in an Avid-sponsored study to determine the amount of radioactivity excreted in urine.

Intervention: Flortaucipir F18